# Medicaments (HS4 3003) Trade Overview | Yugalinks

> Published by **Yugalinks**, global trade intelligence for growing businesses.
>
> [Follow Yugalinks on LinkedIn](https://in.linkedin.com/company/yugalinks)

Medicaments at HS4 3003, with reported global trade through 2024.

Canonical: https://www.yugalinks.com/trade/sector/hs4/3003

## Explore Yugalinks

- [Open the trade workspace](https://www.yugalinks.com/app)
- [Read the methodology](https://www.yugalinks.com/methodology)
- [Review data sources](https://www.yugalinks.com/data-sources)
- [Check data coverage](https://www.yugalinks.com/data-coverage)
- [Read Responsible AI principles](https://www.yugalinks.com/responsible-ai)

## Answer

The medicaments subsector recorded $17.1B in reported global trade in 2024, with +112% annual change.

## Key figures

| Measure | Value |
| --- | --- |
| Latest reported trade | $17.1B |
| Latest annual change | +112% |
| Active exporters | 156 |
| Active importers | 200 |
| Active HS6 products | 10 |

## Annual trend

| Year | Global trade | Corridors | HS6 products |
| --- | ---: | ---: | ---: |
| 1995 | $3.0B | 3,674 | 10 |
| 1996 | $3.3B | 3,678 | 10 |
| 1997 | $3.4B | 3,657 | 10 |
| 1998 | $3.7B | 3,727 | 10 |
| 1999 | $4.3B | 3,892 | 10 |
| 2000 | $4.3B | 4,193 | 10 |
| 2001 | $4.3B | 4,291 | 10 |
| 2002 | $7.0B | 4,339 | 10 |
| 2003 | $8.2B | 4,274 | 10 |
| 2004 | $9.7B | 4,339 | 10 |
| 2005 | $10.4B | 4,346 | 10 |
| 2006 | $11.3B | 4,279 | 10 |
| 2007 | $13.5B | 4,335 | 10 |
| 2008 | $15.3B | 4,435 | 10 |
| 2009 | $14.6B | 4,535 | 10 |
| 2010 | $10.0B | 4,546 | 10 |
| 2011 | $11.8B | 4,498 | 10 |
| 2012 | $11.6B | 4,639 | 10 |
| 2013 | $11.7B | 4,503 | 10 |
| 2014 | $10.8B | 4,716 | 10 |
| 2015 | $10.7B | 4,764 | 10 |
| 2016 | $11.3B | 4,529 | 10 |
| 2017 | $12.0B | 4,390 | 10 |
| 2018 | $17.0B | 4,443 | 10 |
| 2019 | $11.1B | 4,417 | 10 |
| 2020 | $12.0B | 4,557 | 10 |
| 2021 | $9.2B | 4,607 | 10 |
| 2022 | $12.6B | 4,452 | 10 |
| 2023 | $15.9B | 4,388 | 10 |
| 2024 | $17.1B | 4,176 | 10 |

## Leading corridors

- Ireland to Belgium: $3.6B; growth +448.1%.
- Portugal to USA, Puerto Rico and US Virgin Islands: $900.5M; growth +126.2%.
- USA, Puerto Rico and US Virgin Islands to Germany: $864.8M; growth +36%.
- Portugal to Germany: $451.1M; growth +174.3%.
- Switzerland, Liechtenstein to Spain: $413.9M; growth +40.3%.
- Ireland to Portugal: $279.2M; growth +705.1%.
- Singapore to USA, Puerto Rico and US Virgin Islands: $275.5M; growth +3.1%.
- Italy to USA, Puerto Rico and US Virgin Islands: $247.6M; growth +36.2%.
- USA, Puerto Rico and US Virgin Islands to Ireland: $236.7M; growth -23.4%.
- USA, Puerto Rico and US Virgin Islands to Belgium: $217.1M; growth +104.6%.

## HS6 products

- Medicaments: containing penicillins, streptomycins or their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) (HS6 300310)
- Medicaments: containing antibiotics other than penicillins, streptomycins and their derivatives, for therapeutic or prophylactic uses, (not in measured doses, not packaged for retail sale) (HS6 300320)
- Medicaments: containing insulin (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale (HS6 300331)
- Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale (HS6 300339)
- Medicaments: containing alkaloids or their derivatives, (but not containing hormones or antibiotics), for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300340)
- Medicaments: containing alkaloids or their derivatives, containing ephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300341)
- Medicaments: containing alkaloids or their derivatives, containing pseudoephedrine (INN) or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300342)
- Medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300343)
- Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300349)
- Medicaments: containing antimalarial active principles described in subheading note 2 to this chapter, for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300360)
- Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) (HS6 300390)

## Definitions and coverage

Merchandise trade observations aggregated to HS4. Growth, concentration, volatility, and peak comparisons calculated from reported observations. Missing values remain unavailable and are not imputed.

Reported observations cover 1995-2024.

## Continue your research

- [Explore HS4 3003 in the workspace](https://www.yugalinks.com/app?hs=3003)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Other formats

- [HTML](https://www.yugalinks.com/trade/sector/hs4/3003/index.html)
- [JSON](https://www.yugalinks.com/trade/sector/hs4/3003/index.json)
- [JSON-LD](https://www.yugalinks.com/trade/sector/hs4/3003/index.ld.json)


## Continue your research

- [Explore HS4 3003 in the workspace](https://www.yugalinks.com/app?hs=3003)
- [Open the Yugalinks workspace](https://www.yugalinks.com/app)

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-27). [OECD Data Explorer](https://data-explorer.oecd.org/) · [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) · [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) · [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.